What is the current stock price of Calidi Biotherapeutics, Inc. (CLDI)?

As of the latest market data, Calidi Biotherapeutics, Inc. (CLDI) is trading at $0.26. The stock has seen a loss of -0.43% today.

Does Calidi Biotherapeutics, Inc. (CLDI) pay a dividend?

Based on current data, Calidi Biotherapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Calidi Biotherapeutics, Inc.?

The current market capitalization of Calidi Biotherapeutics, Inc. (CLDI) is approximately unavailable.

CLDI

Calidi Biotherapeutics, Inc.·Healthcare

0.26

0.427%(−0.00)

Market Closed

0.27

5.926%(+0.02)

After Hours

Last Updated: — ET

52W L: $0.2152W H: $19.20

CLDI NEWS

globenewswire.com

Mar 27

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.

globenewswire.com

Mar 12

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary manufacturing process for CLD-401, the Company's first lead candidate from its RedTail platform, at the BioProcessing Summit in Barcelona.

globenewswire.com

Mar 9

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

$12 Million of Tranche Warrants Potential Financing Within One Year From Closing $12 Million of Tranche Warrants Potential Financing Within One Year From Closing

globenewswire.com

Mar 6

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing

feeds.benzinga.com

Mar 6

Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why

Calidi Biotherapeutics shares plunged after hours following a public offering announcement, trading near their 52-week low.

globenewswire.com

Mar 5

Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. Each share of common stock or pre-funded warrant will be sold with accompanying common warrants to purchase shares of common stock (or a pre-funded warrant in lieu thereof). The shares of common stock, pre-funded warrants and/or common warrants comprising the units will be separated immediately upon issuance. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in the offering, minus $0.001, the per share exercise price of each pre-funded warrant. In addition, the Company expects to grant the underwriters a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or common warrants to purchase shares of its common stock offered in the public offering at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock, pre-funded warrants and common warrants are being offered by the Company.

Company Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-11-01

Beta

1.42

Websitecalidibio.com↗